EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Radical Resection Versus Organ‐Preserving Local Excision for Rectal Gastrointestinal Stromal Tumor: The Role of Neoadjuvant Imatinib

Byeo Lee Lim iD, Young Il Kim, Jong Lyul Lee, Chang Sik Yu, Hyung-Don Kim iD, Min-Hee Ryu, Chan Wook Kim

Journal of Surgical Oncology · 02.11.2026

DOI: 10.1002/jso.70448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 02.11.2026. Verfasst von Byeo Lee Lim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Colon and Rectum, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rectal gastrointestinal stromal tumors (GISTs) are rare, and their optimal surgical management remains controversial. This study compared clinicopathologic features and oncologic outcomes between total mesorectal excision (TME) and local excision (LE) to guide surgical strategy.

Methods

We retrospectively analyzed 128 patients who underwent surgery for rectal GIST at Asan Medical Center between January 2000 and April 2023. Recurrence‐free survival (RFS), overall survival (OS), and tumor downsizing were evaluated. Survival was measured from surgery or imatinib initiation in patients receiving neoadjuvant imatinib.

Results

Of 128 patients, 43(33.6%) underwent TME and 85(66.4%) underwent LE. Tumors > 5 cm and neoadjuvant imatinib use were more common with TME, whereas tumors < 2 cm and R0 resection were more frequent with LE. The 5‐year RFS did not differ significantly between the LE and TME groups (98.8% vs. 92.6%, p = 0.184), whereas 5‐year OS was higher after LE (96.8% vs. 92.1%, p = 0.047). Neoadjuvant imatinib reduced mean tumor diameter from 64.9 ± 23.5 mm to 49.2 ± 19.3 mm ( p < 0.001).

Conclusion

LE may provide acceptable recurrence control and potential functional advantages in selected patients. For large rectal GISTs, LE may be considered after adequate tumor downsizing with neoadjuvant imatinib.

Schlagwörter

Stichwörter der Autor:innen

gastrointestinal stromal tumorsneoadjuvant therapyorgan sparing treatmentsrectum/surgerysurgical procedures

Autor:innen und Institutionen

  • Division of Colon and Rectum, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Division of Colon and Rectum, Department of Surgery, University of Soonchunhyang College of Medicine, Seoul Soonchunhyang University Hospital, Seoul, Republic of Korea.
  • Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

ORCID-Profile: Byeo Lee Lim, Hyung-Don Kim

Förderung

  • Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea

Zitieren

APA

Lim, B. L., Kim, Y. I., Lee, J. L., Yu, C. S., Kim, H. D., Ryu, M. H., & Kim, C. W. (2026). Radical Resection Versus Organ‐Preserving Local Excision for Rectal Gastrointestinal Stromal Tumor: The Role of Neoadjuvant Imatinib. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70448

Vancouver

Lim BL, Kim YI, Lee JL, Yu CS, Kim HD, Ryu MH, et al. Radical Resection Versus Organ‐Preserving Local Excision for Rectal Gastrointestinal Stromal Tumor: The Role of Neoadjuvant Imatinib. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70448

BibTeX
@article{Lim2026,
  author = {Lim, Byeo Lee and Kim, Young Il and Lee, Jong Lyul and Yu, Chang Sik and Kim, Hyung-Don and Ryu, Min-Hee and Kim, Chan Wook},
  title = {Radical Resection Versus Organ‐Preserving Local Excision for Rectal Gastrointestinal Stromal Tumor: The Role of Neoadjuvant Imatinib},
  journal = {Journal of Surgical Oncology},
  year = {2026},
  doi = {10.1002/jso.70448}
}
Kostenlos starten →